Search PubMed⌕ Search

Biomedical subjects

R E Reisman

Publications and source records attributed to R E Reisman.

At least 19 recordsLinked to original sources
PubMed1997

Hot dog vapor-induced status asthmaticus.

BACKGROUND: Asthma induced by the inhalation of food vapors is unusual and indicative of extreme allergy. Identification of the specific cause and subsequent avoidance is essential. METHODS: We report a patient with asthma who had status asthmaticus following inhalation of boiling hot dog vapors. Prick skin tests were performed to various ingredients of the offending hot dog including chicken, pork, potato, and the aeroallergens. RESULTS: Prick skin tests reacted strongly to chicken and mildly to pork and potato. There was no reaction to aeroallergens. Our patient has not had any acute asthma after avoiding eating and exposure to chicken and hot dog vapors. CONCLUSIONS: Exquisite allergy to chicken was responsible for acute asthma.

Aerosols↗
PubMed1995

Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy.

OBJECTIVES: The purpose of this review was to analyze available relevant data regarding the safety of administering cephalosporins to penicillin-allergic patients, including the significance of penicillin skin test reactions and any difference related to first, second, or third generation cephalosporins. BACKGROUND: Penicillin and cephalosporins both contain a beta-lactam ring. This structural similarity has led to considerable confusion about the cross-allergenicity of these drugs and the risks of allergic reactions from cephalosporins in penicillin-allergic patients. METHODS: Published reports and post-marketing data from pharmaceutical corporations provided the basis for this analysis. RESULTS: The overall incidence of adverse reactions from cephalosporins ranges from 1% to 10%, with rare anaphylaxis (< 0.02%). In patients with histories of penicillin allergy the incidence of cephalosporin reactions is minimally, if at all increased. Post-marketing studies of second and third generation cephalosporins showed no increase in allergic reactions in patients with penicillin allergy histories. Penicillin skin tests do not predict the likelihood of allergic reactions to cephalosporins in patients with histories of penicillin allergy. One reaction occurred in 98 patients (1%) with positive penicillin skin tests and six reactions occurred in 310 patients (2%) with negative tests. CONCLUSIONS: These data indicate that it is safe to administer cephalosporin antibiotics to penicillin-allergic patients and penicillin skin tests do not identify potential reactors.

Cephalosporins↗
PubMed1994

Insect stings.

Explore the source record for details and available documents.

Anaphylaxis↗
PubMed1994

Vancomycin anaphylaxis and successful desensitization.

This report describes vancomycin anaphylaxis and successful desensitization. A 35-year-old woman who tolerated vancomycin initially, developed generalized urticaria and respiratory distress when the drug was readministered. Symptoms recurred following infusion of vancomycin at a lowered rate and dose despite premedication with antihistamines and corticosteroids. Intradermal skin tests with vancomycin were positive at a concentration of 0.1 micrograms/mL. Control subjects reacted at a concentration of 10 micrograms/mL or greater. A rapid 1-day desensitization protocol was unsuccessful. The patient then was "desensitized" by sequential increments in intravenous vancomycin doses over 13 days. After the full therapeutic dose was tolerated, there was a loss of skin test reactivity to vancomycin. We conclude that desensitization to vancomycin is possible and may be the only means to treat an allergic patient adequately when there are no viable therapeutic alternatives.

Adult↗
PubMed1993

Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis.

BACKGROUND: This study assessed the postulate that the adequate duration of venom immunotherapy (VIT) is related to the severity of the initial sting anaphylactic symptoms. METHODS: Data were collected from patients with venom allergy who had sting anaphylaxis and subsequent positive venom skin test results, received maintenance VIT, and had field re-stings after cessation of VIT. There were 217 re-stings in 113 patients with 15 systemic reactions in 10 patients (a re-sting reaction rate of 9% per sting and 7% per patient). RESULTS: Re-sting reactions occurred in 1 of 25 patients with initial mild anaphylaxis (4%), 2 of 41 patients with moderate reactions (5%), and 7 of 47 patients with initial severe symptoms (15%). The results were not influenced by the duration of VIT or the interval between cessation of VIT and the re-sting. Eighteen patients who converted to negative skin test reactions had no reactions when re-stung. CONCLUSIONS: These results suggest a relationship between the severity of anaphylaxis and subsequent duration of VIT. Two to three years is sufficient for patients who had mild to moderate anaphylaxis. Longer duration of therapy is advisable for patients who had severe symptoms and continue to have positive venom skin test results.

Adolescent↗
PubMed1992

Venom immunotherapy: 10 years of experience with administration of single venoms and 50 micrograms maintenance doses.

For the past 10 years, we have administered venom immunotherapy with single venoms, whenever it is possible, and maintenance doses of 50 micrograms. The choice of venoms was based on clinical history, skin test reactions, and a knowledge of venom cross-reactivity. There have been 258 re-stings in 108 patients with only three systemic reactions (2.7% per patient; 1.2% per sting). Two of these re-stings reactions were very mild, hives and facial edema, in patients who had had initial severe anaphylaxis. Five other patients had transient ill-defined symptoms, not considered allergic after re-stings. The patients covered a wide age range. Twenty-seven patients, nine under age 16 years, had initial dermal reactions only, and 44 patients had severe anaphylaxis. Most patients had multiple positive skin tests. Seventy-five patients received single venoms (yellow jacket, 58; honeybee, 15; hornet, 2), and 30 patients received two venoms. Re-stings occurred from 1 month to 8 years, (mean, 2 years) after starting treatment. Results indicate that this approach with 50 micrograms top doses and single venom immunotherapy may be sufficient in most patients with an associated decrease in the cost as well as possible increased morbidity associated with the use of multiple venom antigens.

Adolescent↗
PubMed1992

Stinging insect allergy.

Insect sting anaphylaxis is a relatively common problem estimated to affect at least 0.4% of the population and is responsible for at least 40 deaths per year in the United States. The allergic reactions are mediated by IgE antibodies directed at constituents in honeybee, yellow jacket, hornet, and wasp venoms. In addition, increasing numbers of reactions occur from fire ant stings, non-winged Hymenoptera present in the Southeastern United States. The anaphylactic symptoms are typical of those occurring from any cause. Most reactions in children are mild, frequently involving dermal manifestations (hives, edema) only. The more severe reactions, such as shock and loss of consciousness, can occur at any age but are relatively more common in adults. Following sting anaphylaxis, approximately 50% of unselected patients will continue to have allergic reactions to subsequent stings. The natural history of the disease process is influenced by the severity of the anaphylactic symptoms. Children with dermal reactions only have a benign course and are unlikely to have recurrent reactions. Patients with more severe reactions are at risk for repeat anaphylaxis. Patients with a history of insect sting anaphylaxis and positive venom skin tests should have epinephrine available and are candidates for subsequent venom immunotherapy, which provides almost 100% protection against subsequent re-sting reactions. Recommendations for the duration of immunotherapy are evolving. Venom therapy can be stopped if skin test reactions become negative. For most patients, 3 years of therapy appears adequate, despite persistence of positive venom skin tests.

Animals↗
PubMed1992

Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions.

To examine the postulate that the nature of the symptoms of initial insect sting anaphylaxis is related to the risk and severity of subsequent sting reactions, the results of field re-stings were analyzed in 220 patients who had had venom anaphylaxis and did not receive venom immunotherapy. The incidence of a reaction after the first re-sting was 56% in the total group, was more frequent in adults (74%) than in children (40%), and was unrelated to the time interval since the initial sting reaction. When re-sting reactions did occur, the nature of the symptoms was similar to the symptoms of the initial sting reaction. Reactions to repeated re-stings tended to be similar. Overall, more severe reactions to re-stings occurred eventually in 24 patients. These observations confirm the frequent self-limiting course of insect sting allergy, especially in children, and the repetitive nature of specific anaphylactic symptoms, and the observations thus suggest that patients with mild to moderate anaphylactic symptoms probably do not require venom immunotherapy.

Adolescent↗
PubMed1990

A double-blind study of the effectiveness of a high-efficiency particulate air (HEPA) filter in the treatment of patients with perennial allergic rhinitis and asthma.

This study was designed to assess the effectiveness of a high-efficiency particulate air (HEPA) filter in alleviating allergic respiratory symptoms. Thirty-two patients were studied who had symptomatic perennial rhinitis and/or asthma during the fall and winter months and had a positive skin test with house dust or house dust--mite extract. An ENVIRACAIRE room air cleaner was placed in the bedroom for 8 weeks. In a random manner, the active filter was used for 4 weeks and a blank filter for 4 weeks. There was an average 70% reduction in the particulate matter greater than or equal to 0.3 micron with the HEPA filter. In a double-blind design, results were assessed by analysis of the patients' symptom/medication scores and subjective evaluation. For the total study, there was no difference in the total symptom/medication scores or individual symptom scores during the placebo and active-filter periods. Analysis of the last 2 weeks of each filter period in which respiratory infection was absent demonstrated definite differences in total and individual symptoms, suggesting active-filter benefit. Patients' subjective responses also suggested benefit from the filter. The overall impression is that the HEPA filter can reduce allergic respiratory symptoms.

Adolescent↗